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FOREWORD: 
THE PROMISE AND PERIL OF BIOTECHNOLOGY 
Joan H. Krause* 
1 
Recent years have seen unprecedented growth in biotechnol­
ogy and its potential applications to human health.1 Genetic engi­
neering techniques such as recombinant DNA technology have 
made possible the mass production of life-saving pharmaceutical 
products that previously could only be derived from biological sam­
ples. 2 The identification of the genetic component of many diseases, 
such as breast cancer, has spurred the development of screening 
mechanisms for vulnerable populations.3 Advances in 
pharmacogenetics and gene therapy suggest the tantalizing possibil­
ity that drugs can be tailored for specific responsive populations-_ 
and that some patients' conditions might ultimately be cured by 
"repairing" faulty genes.4 In light of the recent mapping of the 
* Associate Professor of Law, Health Law & Policy Institute, University of Houston Law
Center; J.D. Stanford Law School, B.A. Yale University. I would like to thank Mary Anne
Bobinski for her helpful comments on earlier drafts of this Foreword.
1 Biotechnology is defined as "the collection of industrial processes that involve the use of
biological systems." ROBERT C. KING & WILLIAM D. STANSFIELD, A DICTIONARY OF GENETICS
41 (5th ed. 1997). For purposes of this Symposium, the processes with which we are con­
cerned are those related to health care.
2 Recombinant DNA technology describes a variety of "techniques for joining DNA molecules
in vitro and introducing them into living cells where they replicate." Id. at 291. In the 
pharmaceutical context, recombinant technology may be used to create cells that express a 
naturally-occurring substance, often one that cannot be mass-produced in a synthetic man­
ner. See, e.g., Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd., 927 F.2d 1200, 1203 (Fed. Cir: 
1991) (addressing patent dispute over recombinant technology used to produce the red 
�lood cell stimulator erythropoietin, which previously could only be collected by purify­
ing large quantities of human urine). 
3 See generally Karen H. Rothenberg, Breast Cancer, the Genetic "Quick Fix," and the Jewish
�ommunity: Ethical, Legal, and Social Challenges, 7 HEALTH MATRIX 97 (1997) (describing 
JSSues raised by discovery of the BRCAl gene).
'See, e.g., Mark A Rothstein & Phyllis Griffin Epps, Ethical and Legal Implications of
Pham,acogenomics, 2 NATURE REv. GENETICS 228 (2001) (describing the uses and dangers ofpharmacogenomics); Jesse D. Goldner, Dealing with Conflicts of Interest in Biomedical Re-
1¥1lrch: IRB Oversight as the Next Best Solution to the Abolitionist Approach, 28 J. L. MED. &
Haus. J. HE




the recent debate over 
human cloning-the
biotechn.ology revolutio
n is likely to continue.
5 
Yet the promise of bio
technology will also br
ing challenges-
challenges to the medi
cal, scientific, and patien
t communities, and
to the legal and regul
atory str
uctures that govern the 
development
and commercialization 
of these new biologica
l tools. The ability to
identify and manipula
te genetic material will 
stretch our previous
assumptions about wh
at can (and should) be 
protected by patent
law, and whether tissu
e donors have any righ
t to share in the bene­
fits of the discoveries 
they help create. 
The necessity of exam
ining
large numbers of gene
tic samples will raise q
uestions regarding pa­
tient's motivations for 
assisting in research e
fforts, and whether ex­
isting law adequatel
y protects patient in
terests. The burgeoning
number of commercially 
available biotechnology 
products will force 
the Food and Drug A
dministration ("FDA") 
to reevaluate its tradi-
tional standardized a
pproach to pharmaceuti
cal regulation. And in
a competitive market, 
where allegations of wi
despread misconduct
already exist, the p
otential for the develop
ment of genetically tai
­
lored pharmaceutical 
products will increase 
pressure on manufac­
turers to reco
up their investments 
from a significantly 
smaller 
customer base. 
The authors in this Sy
mposium address the 
challenges posed
by biotechnolo
gy in the heal
th care fraud, regulato
ry, and patent 
protection contexts . W




es the ways in which
biotechnology stretches 
the boundaries of trad
itional health care
and intellectual prope
rty regulation. Finding 
the proper balance is a
difficult task: lack of re
gulation may leave mil
lions of patients vul­
nerable to abuse, while 
overly restrictive la
ws pose the risk of free
z­
ing the industry in its 
current undeveloped 
state . The suggestions 
made by these autho
rs, and their careful an
alyses of the pr
oblems,
will go a long way tow
ard helping us achieve 
that balance. 
In the 2002 Jenkins & 
Gilchrist Health Law L
ecture, Assistant
United States Attorney J
ames Sheehan addresses 
the challenges fac-
Enucs 379 -80 (2000) 
(describing failed gen
e thernpy experiment 
involving l�yea,-old
Jesse Gelsing«); Alle
n D. Roses. Ph_,m,roge
netics ,nd the P""tice of 
Medidm. 405 NA-nm£
857 (2000) (describin
g significance of phar
macogenetic tools for m
edical practice). 
'Se<, e.g., National Inst





Ornrt·· of Human Gen
ome Gune 26, 2000),
""'"''" ,t http,/ /ww
w.nih.gov/news/ P' / 
jun2000 / nhgri-26.hbn; 
Lod B. Andrews, J;
Thm o Right to Cl""'? 
Constitution,! Challeng,s 
to B,ns on Hu""'" Clo
ning, 11 HARV, J.L. &
TECH- 643 (1998) (discu
ssing cloning debate). 
. 
3 
mg biotechnology in th h 
biotechnology as 
e p. armaceutical context.6 Sheeh 1 k 
t d
. . a potential soluti 
an oo s to
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;t ;anal pharmaceutical treatment
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a problem that plagues
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e act that many drugs sim-
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han attributes this problem to � 
whom_ they are prescribed.'
o industrial way" of stand d ' 
ur continued adherence to an 
The traditional system has a nu:bIZ
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er of advantages, including stan­
and regulation of pharmaceuti�:
ent, mass production, marketin 
ard1ze dosing regimens. But the st��
ducts, and the ability to stanl
mflcant dis_advantages, including a la 
archzed approach also has sig-
non-comphance with dru . 
rge number of adverse eff 
t�iden:fy which patient
! .:';f:'.:;::;: to s!de effects, the inab
�:
a JUSt rug regimens based on s 
o a rug, and the failure to
potential for "customizing" d 
ubsequent data., Biotechnolog , 




ise m alleviating these probl�ms. 
a w at dose-offers great prom-
In Sheehan, s view h 
shad_owed by the specter'of f
�:".i';er, biotechnology's promise is
fraud posmg a threat to vulnerable 
a particularly insidious type of
rvolvmg clear violations of posi
f 
p�tient popu_lations. Rather than
. oc�es on ''breach[es] of good fa::: 
a� ;bhgat10ns, this new fraud
m t  e community[,] involvin a d  
an . au deahng as understood
order to identify such co 
g . ecephon or breach of trust 
"10 I 
that we 1 k 
mmuruty bounda . Sh 
. n 
. . oo to the broader ethi 1 
nes, eehan suggests 
med1cme 11 Wh 
ca standards g . 
. ereas traditional med · 1 f 
overnmg science and 
ica raud has involved . issues
6 James G Sh h . - ee an, Bzotechnology & Fraud 2 
7 Id. at 13-14. 
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9 Id. at 15-16. 
io Id. at 17 Of - course, pursuing h " 
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mary health care f d 
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e the utilization of a broader 
where the def d 
rau weapon, the Civil False Cla · 
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example, the government's pri-
en ant sub ·t 
rms ct ("FCA") 
While failure t 
m1 s a monetary "claim" t th 
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o comply with d I 
o e governme t 31 U 
generally require that co r 






ment's payment of 
m? iance with such obli ations 
es v10 ate the FCA, courts
Paradigms of Govern!e clarm. See Joan H. 
Kraus!, Healthbe expressl_Y linked to the govern
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(2001) (analyzing fals�;e�� 
�nder the Civil False Claim�::/;
ovzders and the Public Fisc:
p
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ous ·�reaches of trust" -�
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6 GA. L. REv. 121, 175-81 
t traditional cons ir 
m1g t have to be brought und 
ac ons based on more amor­
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f�se statements laws. See e
er other causes of action, such as 
n Sheehan 
p ohib1ting false statements) 
, .g., 18 U.S.C. §§ 371 (prohibiting 
' supra note 6, at 18. 
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of billing and reim
bursement, Sheehan b
elieves that fraud in 
the 
biotechnology era will 
focus more broadly o
n what happens to p
a·
tients in these health 
care settings. 
This new type of fra
ud will encompass a 
wide range of imper·
missible activities, in
cluding reckless endan
germent of patients 
and 
the provision of medi
cally unnecessary test
s and treatment. She
ehan
is particularly interest
ed in fraud that occur
s in the research con
text, 
where patient-subjects 
may be unaware of 
the dangers, risks, an
d
financial conflicts of 




s of prosecuting res
earch fraud, Sheehan 
indi· 
cates that federal la
w enforcement offic
ials plan to pursue 
these 
types of cases in the f
uture . Sheehan conclu
des by offering gen
eral






de full disclosure to 
pa· 
tients of all risks and 
financial incentives in
volved in the study, 
re·
port all relevant sid
e effects, design stu
dies to achieve legit
imate
research (rather than 
marketing) goals, an
d give researchers 
the
freedom to publish th
eir results in an hones
t and unbiased ma
n·
nerB In Sheehan' s vi
ew, only by proactive 
efforts on the part of 
the
individuals, instituti
ons, and cm:runercial 
entities involved in 
re·
search can the potent
ial for biotechnology 
fraud be alleviated. 
Professor Michael M
alinowski addresses o
ne of Sheehan' s ini·
tial assumptions: tha
t recent advances in g
enetic profiling will 
en·
able us to deten:rrine 
which patient popula
tions are likely to be
nefit
from individual drug
s, and perhaps one d
ay to tailor drugs to 
indi· 
vidual patients.14 Ma
linowski argues that th
e pharmaceutical ind
us·
try is under unpre
cedented competitive 
pressures due to th
e
growing influence of 
the generic drug ind






have responded by d
evoting an increasing 




ties . Like Sheehan, 
Mali·
nowski argues that 
traditional R&D acti
vities-a focus on clin
ical
trials, supplemented 
by reports of individu
al physician experien
ces
with a new drug-lea
ve significant gaps in 
our ability to treat in
di­
vidual patients. In co
ntrast, recent advances 
in genetic testing ha
ve
12 Id. at 19-21. 
13 Id. at 25-29. 
"Michael J. Malinow
ski, !Aw, Policy, ,ml 
Mo,lret Implicat;ons of 
Gerten, Pmjiling ;n o,u
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(2002). 
made it po "bl 
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precedented precision in resc�· 
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As Malinowski d 
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the public receives from the disclosure of the patented invention.21 
Many substances, such as "products of nature," are not patentable
because the public would not gain any new knowledge in ex­
change.22 While courts have upheld patents of isolated and purified 
forms of naturally occurring substances, it is not clear that genetic
material, standing alone, meets the criteria for patentability. Moreo­
ver, restricting access to diagnosis and treatment involving genetic
information-the practical effects of patent exclusivity-may have
enormous social costs in the health care context.23 
Andrews argues that the very exclusivity rights that make pat­
ents so attractive pose significant obstacles for the advancement of 
science and medicine. As a practical matter, the possibility of ob­
taining patent protection creates an impediment to research by giv­
ing researchers incentives to hoard samples and delay publication of 
results in an attempt to protect their patent rights (and hence their 
commercial interests).24 Similarly, the costs of obtaining a license
may prevent others from engaging in further research using a pat­
ented gene sequence, including studies needed to confirm the verac­
ity and utility of the original discovery.25 Patents also interfere with 
the traditional scientific process of "cumulative investigation" by 
forcing research�rs to pay for costly access to samples, databases, 
and other necessary information-costs that will be reflected in the
price of the resulting products.26 And the pressure to quickly patent 
new genetic discoveries, long before the functions of the patented 
sequences can be established, may lead to the granting of "subma­
rine" patents that can unexpectedly derail ongoing research related 
to those sequences.
27 
In addition to these broader scientific concerns, gene patents 
also affect the delivery of health care services. The fact that one com­
pany holds the patent on a gene associated with a particular disease
may prevent other researchers from engaging in future research in­
volving that disease, particularly where the patent holder refuses to 
license competing laboratories to test for the gene.28 Gene patents 
21 Id. at 67-68. 
22 Id. 
23 Id. at 69. 
24 Id. at 80. 
25 Andrews, supra 20, at 81. 
26 Id. at 83. 
27 Id. 
28 Id. at 85. 
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rived from more common genetic sources).
36 Regardless of the alter­
native chosen, however, Andrews stresses the 
need for a policy to
assure that patented genetic material remains 
accessible to patients
and researchers and is used to promote posit
ive social advances . 
Professor Cynthia Ho expands on Andrews' 
final policy query:
what rights should patients have in biotechn
ology inventions based
on their genetic material?37 Ho argues that p
atients who contribute
to genetic research m
ay not be aware the r
esearch could lead to 
pat­
ented discoveries that confer exclusive rights 
on the patent holder. 
Ho traces the roots of such misconceptions 
to widespread patient
misunderstanding, including the mistaken 
assumption that doctors
and researchers 
are immune from commercial interests, and 
to gen­
eral misconceptions about the nature of patent 
protection .38 The re­




commercialized, making new technologies 
extremely expensive­
and perhaps inaccessi
ble to the very patie
nts whose genetic co
ntri-
butions made those discoveries possible . 
Despite arguments th
at patients deserve to 
share in the profits
from these discoveries, Ho argues that the _p
atent laws are not de­
signed to protect m
ere sources of scien
tific information or 
ideas.
Patents protect "inve
ntors" who make d
iscoveries regarding 
the
substances they study, such as identifying th
e function of a particu­
lar genetic sequence 
(rather than simply id
entifying the existen
ce of 
a genetic anomaly)." 
Under current law, p
atients do not engage 
in 
any inventive activities that would grant the
m a role in the concep­
tion of the patented discovery; their mere g
enetic material, existing
in its natural state, is not patentable subject 
matter.40 
Given these restrictions, can patients ever ho
pe to share in the
scientific discoveries made with their genetic 
information? While ac­
knowledging the policy arguments in favor o
f amending the laws of
joint inventorship t
o recognize a role fo
r patients, Ho arg
ues that
current legal interpretations regarding the righ
ts of joint inventors­
as well as opposition from corporate intere
sts-make this an un-
36 Id. at 105. 
37 Cynthia M. Ho, Who 
Deserves the Patent Pot 
of Gold?: An Inquiry 
into the Proper Invento
rship
of Patient-Based Disc
overies, 2 Rous. J. HEA
LTH L. & PoL'Y 107 
(2002). 
38 Id. at 122-25.
39 Id. at 125. 
40 Id. at 133-37. For simil
ar reasons, patients are 
unlikely to be considered 
'1oint" inventors of 
a discovery (as several 
litigious patients have 
already discovered). Id. 
at 136-37. 
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